# A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer

> **NCT03843918** · PHASE1,PHASE2 · TERMINATED · sponsor: **Laekna Limited** · enrollment: 33 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** LAE001

## Key facts

- **NCT ID:** NCT03843918
- **Lead sponsor:** Laekna Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-05
- **Primary completion:** 2023-10-09
- **Final completion:** 2023-10-09
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** This is phase I/II study, phase I study completed, phase II study started and enrolled 1 patient. Company strategy consideration to terminated phase 2 study finally.
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03843918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03843918, "A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03843918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*